(Q40780019)

23 September 2017

title

Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells (English)

1 reference

23 September 2017

Fukuoka K

1

1 reference

23 September 2017

Usuda J

2

1 reference

23 September 2017

Iwamoto Y

3

1 reference

23 September 2017

Fukumoto H

4

1 reference

23 September 2017

Nakamura T

5

1 reference

23 September 2017

Yoneda T

6

1 reference

23 September 2017

Narita N

7

1 reference

23 September 2017

Saijo N

8

1 reference

23 September 2017

Nishio K

9

1 reference

23 September 2017

publication date

1 January 2001

1 reference

Investigational New Drugs

23 September 2017

published in

1 reference

23 September 2017

volume

19

1 reference

23 September 2017

issue

3

1 reference

23 September 2017

page(s)

219-227

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1010608317361

23 September 2017

exact match

0 references

cites work

Neuronal Differentiation of Neuro 2a Cells by Inhibitors of Cell Cycle Progression, Trichostatin A and Butyrolactone I

1 reference

12 December 2020

A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression.

1 reference

12 December 2020

Oncoprotein signalling and mitosis

1 reference

12 December 2020

Cis-diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung-cancer cells

1 reference

12 December 2020

Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin

1 reference

12 December 2020

Phase I study of E7010

1 reference

12 December 2020

Chemical inhibitors of cyclin-dependent kinases.

1 reference

12 December 2020

Ectopic p16(ink4) expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells

1 reference

12 December 2020

Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance

1 reference

12 December 2020

Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target

1 reference

12 December 2020

The retinoblastoma protein and cell cycle control

1 reference

12 December 2020

Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle

1 reference

12 December 2020

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

1 reference

12 December 2020

Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function

1 reference

12 December 2020

Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age

1 reference

12 December 2020

Cdc2 regulatory factors

1 reference

12 December 2020

The kinase inhibitor staurosporine induces G1 arrest at two points: effect on retinoblastoma protein phosphorylation and cyclin-dependent kinase 2 in normal and transformed cells.

1 reference

12 December 2020

The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity

1 reference

12 December 2020

The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity

1 reference

12 December 2020

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

12 December 2020

Inhibition of G1 cyclin expression in normal rat kidney cells by inostamycin, a phosphatidylinositol synthesis inhibitor

1 reference

12 December 2020

Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells

1 reference

12 December 2020

Novel sulfonamides as potential, systemically active antitumor agents

1 reference

12 December 2020

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

1 reference

12 December 2020

Reversible tyrosine phosphorylation and cell cycle control

1 reference

12 December 2020

Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle

1 reference

12 December 2020

1 reference

12 December 2020

Detection of a novel cell cycle-regulated kinase activity that associates with the amino terminus of the retinoblastoma protein in G2/M phases

1 reference

12 December 2020

Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines.

1 reference

12 December 2020

Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer

1 reference

12 December 2020

Inhibition of cyclin D1 expression and phosphorylation of retinoblastoma protein by phosmidosine, a nucleotide antibiotic.

1 reference

12 December 2020

G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1010608317361

1 reference

Dimensions Publication ID

23 September 2017

1047721144

0 references

1 reference